USSTOCK.TODAY
Regular Market
Log in Sign up

Arcus Biosciences shares fall after clinical data release; Salesforce pursues Braze acquisition

Investing.com +1 ·

RCUS
RCUS Arcus Biosciences Inc
$22.14 +0.09%
View chart & analysis →
  1. 1Arcus Biosciences shares fell 6% today.
  2. 2Salesforce is pursuing the acquisition of Braze for $5.7 billion.
  3. 3The Phase 3 PEAK-20 study is scheduled to begin by the end of this year.

So what's the key point?

Arcus Biosciences shares dropped by about 6 percent. News also arrived that Salesforce is looking to acquire Braze.

Source Investing.com +1 · View original ↗

Related 3-line summaries

Summit Therapeutics shares rise as ivonescimab lung cancer survival data improves InvestorsHub +2 · Jul 24W. R. Berkley Corp shares fall 3.4% in after-hours trading as Q3 revenue misses estimates Investing.com +1 · 1h agoAmazon plans to hire more than 300,000 workers for the upcoming holiday season The Wall Street Journal +2 · 1h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news